A 55-year-old man with acute myocardial infarction complicated by recurrent ventricular ectopics is started on intravenous lidocaine. Which of the following best explains why lidocaine is preferred over quinidine in the acute post-MI setting?

Why Lidocaine Is Preferred in Acute Post-MI Ectopy

Class I Antiarrhythmics: Quinidine vs Lidocaine

Both quinidine and lidocaine are Class I antiarrhythmics (sodium channel blockers), but they differ significantly in their hemodynamic profile and safety in the acute MI setting.

Why Each Option Is Evaluated

Option 1 (Incorrect): While lidocaine does have a faster onset (true for IV formulation), the statement that it "does not depress myocardial contractility" is misleading. Lidocaine DOES depress contractility, but the effect is minimal compared to quinidine. The key advantage is not the absence of negative inotropic effect, but the minimal effect combined with lack of anticholinergic properties.

Option 2 (CORRECT): This accurately captures the hemodynamic advantage. Quinidine's negative inotropic effect (which can precipitate cardiogenic shock in acute MI) combined with its anticholinergic properties (reflex tachycardia, increased AV conduction) make it unsuitable. Lidocaine avoids both pitfalls.

Option 3 (Incorrect): While lidocaine is hepatically metabolized and has a shorter half-life (~1.5–2 hours), this is not the PRIMARY reason for preferring it in acute MI. The main advantage is hemodynamic safety, not pharmacokinetic reversibility. Quinidine's longer half-life is not the reason it is avoided.

Option 4 (Incorrect): Lidocaine is NOT superior to quinidine in preventing sudden cardiac death. In fact, the CAST trial (Cardiac Arrhythmia Suppression Trial) showed that Class I antiarrhythmics, including lidocaine, do NOT improve mortality in post-MI patients and may increase it. Modern practice uses beta-blockers and ACE inhibitors for post-MI risk reduction, not Class I drugs for long-term suppression.

High-Yield Summary